Zobrazeno 1 - 2
of 2
pro vyhledávání: '"I. Semizarova"'
Autor:
R. Samigullina, N. Kiryukhina, T. Salnikova, T. Rasevich, Nasonov El, E. Kalinina, I. Semizarova, I. Bashkova, D. Kretchikova, D. Bobrikova, I. Vinogradova, V. Sorotskaya, E. Koltsova, A. Dyo, I. Shchendrigin, O. Semagina, A. Dadalova, M. Semchenkova, D. Murtazalieva, Alexander Lila, V. Mazurov, D. Chakieva, A. Davydova, I. Shafieva, A. Baranov, N. Lapkina, I. M. Marusenko, I. Kushnir, A. Karateev
Publikováno v:
Annals of the Rheumatic Diseases. 80:1095.3-1096
Background:JAK inhibitors block intracellular signaling pathways responsible for the synthesis of cytokines and mediators involved in the development of chronic pain and central sensitization (CS). This determines a very rapid clinical response to JA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77f9af1890928d01dac7b7df61f2fca8
https://doi.org/10.1136/annrheumdis-2021-eular.2902
https://doi.org/10.1136/annrheumdis-2021-eular.2902
Autor:
R. Samigullina, A. Davydova, Diana Abdulganieva, A. R. Babaeva, Galina Lukina, E. Kalinina, T. Rasevich, V. Mazurov, O. Slyusar, Nasonov El, I. Semizarova
Publikováno v:
Annals of the Rheumatic Diseases. 79:639-639
Background:Current EULAR and national guidelines recommend use of synthetic target drug Tofacitinib (TOFA) for active rheumatoid arthritis (RA) treatment in case of resistance or intolerance to metotrexate (MTX) or other conventional DMARDs. Two trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d68575089d8685b3ac85010c8fc9321
https://doi.org/10.1136/annrheumdis-2020-eular.3662
https://doi.org/10.1136/annrheumdis-2020-eular.3662